A61P 11/10
Expectorants
A61P11/10 (Expectorants) appears on 356 US grants and 410 published applications in this corpus.
Search patents in A61P- Granted patents
- 356
- Published applications
- 410
- Assignees
- 251
- Inventors
- 1,091
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 2 | 0 |
| 1978 | 3 | 0 |
| 1979 | 4 | 0 |
| 1980 | 1 | 0 |
| 1981 | 2 | 0 |
| 1982 | 0 | 0 |
| 1983 | 4 | 0 |
| 1984 | 6 | 0 |
| 1985 | 5 | 0 |
| 1986 | 7 | 0 |
| 1987 | 7 | 0 |
| 1988 | 8 | 0 |
| 1989 | 8 | 0 |
| 1990 | 5 | 0 |
| 1991 | 5 | 0 |
| 1992 | 3 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 8 | 0 |
| 1998 | 7 | 0 |
| 1999 | 6 | 0 |
| 2000 | 8 | 0 |
| 2001 | 13 | 5 |
| 2002 | 9 | 12 |
| 2003 | 8 | 23 |
| 2004 | 7 | 24 |
| 2005 | 8 | 25 |
| 2006 | 6 | 14 |
| 2007 | 11 | 21 |
| 2008 | 9 | 26 |
| 2009 | 16 | 24 |
| 2010 | 11 | 28 |
| 2011 | 18 | 25 |
| 2012 | 17 | 16 |
| 2013 | 15 | 27 |
| 2014 | 20 | 18 |
| 2015 | 12 | 16 |
| 2016 | 15 | 13 |
| 2017 | 9 | 13 |
| 2018 | 10 | 12 |
| 2019 | 9 | 16 |
| 2020 | 5 | 9 |
| 2021 | 3 | 9 |
| 2022 | 5 | 12 |
| 2023 | 1 | 10 |
| 2024 | 4 | 4 |
| 2025 | 6 | 3 |
| 2026 | 4 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- N-(pyridin-2-yl)-6,7,8,9-tetrahydro-5h-5,8-epiminocyclohepta[c]pyridine-10-carboxamide derivatives and similar compounds as GPR65 modulators for the treatment of cancer9 Jun 2026US 12,649,744 B2Pathios Therapeutics Limited
- Linear polysaccharide based film products12 May 2026US 12,622,971 B2Aquestive Therapeutics, Inc.
- 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)12 May 2026US 12,624,028 B2Vertex Pharmaceuticals Incorporated
- Isochromene derivatives as phosphoinositide 3-kinases inhibitors20 Jan 2026US 12,527,797 B2Chiesi Farmaceutici S.P. A.
- Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)23 Dec 2025US 12,502,376 B2Vertex Pharmaceuticals Incorporated
- Lung-Specific Targeting-Peptide (LTP), Compositions, and Uses Thereof27 Aug 2026US 2026/0250319 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Keratin cf1, preparation method therefor, pharmaceutical composition comprising same, and use thereof16 Jul 2026US 2026/0201002 A1Institute of Materia Medica, Chinese Academy of Medical Sciences
- Fudosteine nebulization inhalation solution composition, drug assembly, and use thereof29 Jan 2026US 2026/0027046 A1Beijing Increase Innovative Drug Co., LTD
- Product and process for mucus viscosity normalization29 Jan 2026US 2026/0027189 A1Orpro Therapeutics, Inc.
- Pharmaceutical Combinations for Treatment8 Jan 2026US 2026/0007621 A1MFS Pharmaceuticals Ltd.
Most cited
By later US patents
- Fast dissolving orally comsumable films222US 6,596,298 B2Warner-Lambert Company · 2003
- Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom119US 7,425,292 B2Monosol Rx, LLC · 2008
- Oral liquid mucoadhesive compounds117US 6,319,513 B1The Procter & Gamble Company · 2001
- Method and device for the provocation of air passage narrowing and/or the induction of sputum116US 5,817,028 ACentral Sydney Area Health Service · 1998
- Method of treating lung disease with uridine triphosphates107US 5,292,498 AThe University of North Carolina at Chapel Hill · 1994